Status:
ACTIVE_NOT_RECRUITING
SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER
Lead Sponsor:
Pfizer
Conditions:
Respiratory Syncytial Virus Infection
Eligibility:
All Genders
60+ years
Brief Summary
This post-marketing study is a multicenter cohort study in individuals aged 60 years or older vaccinated with Abrysvo (RSV vaccine）designed to confirm the safety in individuals aged 60 years or older ...
Eligibility Criteria
Inclusion
- Individuals aged 60 years or older who have been vaccinated with Abrysvo for the first time after Abrysvo is launched. Those who have previously participated in the clinical trials of this product will be excluded.
- Vaccinated participants (or his/her legally acceptable representative) who understand the information on this study and have provided written consent regarding their participation in the study.
Exclusion
- There are no exclusion criteria for this study.
Key Trial Info
Start Date :
May 27 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 27 2029
Estimated Enrollment :
1100 Patients enrolled
Trial Details
Trial ID
NCT06546800
Start Date
May 27 2025
End Date
February 27 2029
Last Update
December 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer
Tokyo, Japan